Spots Global Cancer Trial Database for docetaxel and cisplatin
Every month we try and update this database with for docetaxel and cisplatin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) | NCT00995761 | Non-small Cell ... | Docetaxel and C... | 18 Years - 75 Years | Gyeongsang National University Hospital | |
| Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) | NCT00995761 | Non-small Cell ... | Docetaxel and C... | 18 Years - 75 Years | Gyeongsang National University Hospital | |
| FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer | NCT03067792 | Inoperable Gast... | 5-fluorouracil,... docetaxel and c... | 19 Years - 75 Years | Yonsei University | |
| Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer | NCT00772863 | Ovarian Neoplas... | docetaxel and c... | 18 Years - 70 Years | Sanofi | |
| Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients | NCT00271323 | Non-Small-Cell ... | docetaxel and c... radiotherapy | 18 Years - 75 Years | Sanofi | |
| Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | NCT01516996 | Oropharyngeal C... Hypopharyngeal ... | docetaxel and c... IMRT Nimotuzumab | 18 Years - 70 Years | The Second People's Hospital of Sichuan | |
| Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer | NCT01551589 | Esophageal Squa... | Involved Field ... docetaxel and c... Elective Nodal ... | 18 Years - 80 Years | The Second People's Hospital of Sichuan | |
| Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery | NCT00238407 | Esophageal Canc... | Docetaxel and C... Radiotherapy | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | NCT01516996 | Oropharyngeal C... Hypopharyngeal ... | docetaxel and c... IMRT Nimotuzumab | 18 Years - 70 Years | The Second People's Hospital of Sichuan | |
| Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer | NCT00521521 | Head and Neck N... | docetaxel and c... docetaxel | 18 Years - 70 Years | Sanofi | |
| Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer | NCT00521521 | Head and Neck N... | docetaxel and c... docetaxel | 18 Years - 70 Years | Sanofi | |
| Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer | NCT01551589 | Esophageal Squa... | Involved Field ... docetaxel and c... Elective Nodal ... | 18 Years - 80 Years | The Second People's Hospital of Sichuan | |
| Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer | NCT00772863 | Ovarian Neoplas... | docetaxel and c... | 18 Years - 70 Years | Sanofi | |
| The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC) | NCT00887315 | Non-small Cell ... | Docetaxel and c... Docetaxel and c... | 18 Years - | University of Chicago | |
| FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer | NCT03067792 | Inoperable Gast... | 5-fluorouracil,... docetaxel and c... | 19 Years - 75 Years | Yonsei University | |
| Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | NCT02577341 | Non-small-cell ... | Nimotuzumab docetaxel and c... daily RT to the... | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
